Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | PNMT | P11086 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11006111 | 0.84 | ALDH1A1 (0.46) | ALDH1A1PNMTLMNAPOLBP2RX7 | |
| SCHEMBL8094251 | 0.82 | ALDH1A1 (0.45) | ALDH1A1PNMTLMNAPOLBP2RX7 | |
| SCHEMBL599099 | 0.82 | GABRA1 (0.57) | GABRA1GABRB2MAPT | |
| SCHEMBL3119523 | 0.81 | ALDH1A1 (0.48) | ALDH1A1PNMTLMNAP2RX7HPGD | |
| Ammonia Solution, Strong SCHEMBL9357829 | 0.79 | GABRA1 (0.55) | GABRA1GABRB2MAPT | |
| Water SCHEMBL28182555 | 0.79 | GABRA1 (0.55) | GABRA1GABRB2MAPT | |
| SCHEMBL724659 | 0.79 | ALDH1A1 (0.46) | ALDH1A1PNMTLMNAP2RX7HPGD | |
| SCHEMBL9784664 | 0.79 | ALDH1A1 (0.46) | ALDH1A1PNMTLMNAP2RX7HPGD | |
| SCHEMBL5066645 | 0.79 | ALDH1A1 (0.46) | ALDH1A1PNMTLMNAP2RX7HPGD | |
| SCHEMBL14142844 | 0.79 | ALDH1A1 (0.46) | ALDH1A1PNMTLMNAP2RX7HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0244167-B1 | IMPROVED PROCESS FOR PREPARING POLY (ARYL ETHERS) AND POLY (ARYL ETHER KETONES) | AMOCO CORPORATION (US) | 1990-04-04 | — | — | EP | claimed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| WO-2023020457-A1 | PYRIDAZINONE OR PYRIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022271679-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220162203-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | VORONOI INC. (KR) | 2022-05-26 | — | — | US | disclosed |
| WO-2022094271-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-7601841-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-2003131-A1 | AMINOPYRROLIDINE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-7230023-B2 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2007-06-12 | — | — | US | disclosed |
| EP-1053990-A2 | A method of producing an aromatic ketone and an aromatic ketone composition containing it | TORAY INDUSTRIES, INC. (JP) | 2000-11-22 | — | — | EP | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
| EP-0175122-A2 | Process for the manufacture of polymers containing reactive end groups | BAYER AG (DE) | 1986-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | ALDH1A1 2674/4885GABRA1 373/4885GABRB2 670/4885 |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | ALDH1A1 796/4885GABRA1 1711/4885GABRB2 1925/4885 |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | ALDH1A1 2758/4885GABRA1 2064/4885GABRB2 3462/4885 |
| US-20220162203-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | ERBB4, ERBB2, EGFR | ALDH1A1 3534/4885GABRA1 2212/4885GABRB2 1869/4885 |
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | GRM5, GRIK5, GRM3 | ALDH1A1 3053/4885GABRA1 103/4885GABRB2 148/4885 |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARG, PPARA, PPARD | ALDH1A1 3192/4885GABRA1 1363/4885GABRB2 1068/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1158/4885GABRA1 4281/4885GABRB2 4142/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3208/4885GABRA1 3975/4885GABRB2 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.